{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-245181","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2026-05-28T20:05:17+00:00","discovered_at":"2026-05-28T20:07:00.324691+00:00","generated_at":"2026-05-28T21:21:21.199443+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Standard BioTools approves severance plans for CEO, CFO, and CBO through 2028","bullets":["2026 Severance Plan for CFO Alex Kim and CBO Sean Mackay: outside COC, 12 months salary, prorated bonus, COBRA subsidy, equity acceleration if terminated by Aug 27, 2026.","During COC: non-CEOs receive 150% of salary plus target bonus lump sum, 18 months COBRA, and full equity vesting.","CEO Michael Egholm covered under 2023 Severance Plan: outside COC, 200% salary over 24 months, 12 months COBRA, outplacement.","During COC: CEO gets 250% of salary plus bonus lump sum, 30 months COBRA, and full equity vesting.","2026 Severance Plan supersedes the 2024 plan; both plans expire August 4, 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-245181","json":"https://secwatch.observer/filing/0001193125-26-245181.json","markdown":"https://secwatch.observer/filing/0001193125-26-245181.md","text":"https://secwatch.observer/filing/0001193125-26-245181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526245181/0001193125-26-245181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312526245181/lab-20260521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T21:21:21.199443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001108524-26-000131","ticker":"CRM","company_name":"Salesforce, Inc.","filed_at":"2026-06-01T20:43:09+00:00","headline":"Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected","event_type":"other_material","sec_items":["5.07","5.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001108524-26-000131","json":"https://secwatch.observer/filing/0001108524-26-000131.json","markdown":"https://secwatch.observer/filing/0001108524-26-000131.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/0001108524-26-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108524/000110852426000131/crm-20260528.htm"},"side_by_side_evidence":null},{"accession":"0000790816-26-000019","ticker":null,"company_name":"BRANDYWINE OPERATING PARTNERSHIP, L.P.","filed_at":"2026-06-01T20:30:42+00:00","headline":"Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP","event_type":"other_material","sec_items":["1.01","2.03","5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000790816-26-000019","json":"https://secwatch.observer/filing/0000790816-26-000019.json","markdown":"https://secwatch.observer/filing/0000790816-26-000019.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1060386/000079081626000019/0000790816-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/790816/000079081626000019/bdn-20260528.htm"},"side_by_side_evidence":null},{"accession":"0000908937-26-000015","ticker":"SIRI","company_name":"SIRIUS XM HOLDINGS INC.","filed_at":"2026-06-01T20:28:55+00:00","headline":"Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000908937-26-000015","json":"https://secwatch.observer/filing/0000908937-26-000015.json","markdown":"https://secwatch.observer/filing/0000908937-26-000015.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/0000908937-26-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908937/000090893726000015/siri-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039518","ticker":"ESPR","company_name":"Esperion Therapeutics, Inc.","filed_at":"2026-06-01T20:22:15+00:00","headline":"Esperion shareholders approve 7M-share increase to 2022 equity incentive plan","event_type":"other_material","sec_items":["5.02","5.07","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039518","json":"https://secwatch.observer/filing/0001628280-26-039518.json","markdown":"https://secwatch.observer/filing/0001628280-26-039518.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001449794-26-000012","ticker":"EMYB","company_name":"Embassy Bancorp, Inc.","filed_at":"2026-06-01T20:37:17+00:00","headline":"Embassy Bancorp expands stock repurchase program by additional $5M","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001449794-26-000012","json":"https://secwatch.observer/filing/0001449794-26-000012.json","markdown":"https://secwatch.observer/filing/0001449794-26-000012.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/0001449794-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1449794/000144979426000012/emyb-20260601x8k.htm"},"side_by_side_evidence":null},{"accession":"0001288469-26-000045","ticker":"MXL","company_name":"MAXLINEAR, INC","filed_at":"2026-06-01T20:35:55+00:00","headline":"MaxLinear dismisses Grant Thornton, appoints KPMG as auditor for FY2026","event_type":"other_material","sec_items":["4.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001288469-26-000045","json":"https://secwatch.observer/filing/0001288469-26-000045.json","markdown":"https://secwatch.observer/filing/0001288469-26-000045.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1288469/000128846926000045/0001288469-26-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1288469/000128846926000045/mxl-20260528.htm"},"side_by_side_evidence":null},{"accession":"0002024218-26-000078","ticker":"SMC","company_name":"Summit Midstream Corp","filed_at":"2026-06-01T20:31:58+00:00","headline":"Summit Midstream Corporation announces inaugural $35 million stock repurchase program","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002024218-26-000078","json":"https://secwatch.observer/filing/0002024218-26-000078.json","markdown":"https://secwatch.observer/filing/0002024218-26-000078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024218/000202421826000078/0002024218-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024218/000202421826000078/smc-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063531","ticker":"CTXR","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-06-01T20:30:19+00:00","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063531","json":"https://secwatch.observer/filing/0001213900-26-063531.json","markdown":"https://secwatch.observer/filing/0001213900-26-063531.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}